These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15549649)

  • 1. Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading.
    Ichinose Y; Tanaka H; Inoue M; Mochizuki S; Tsuda E; Seino Y
    Calcif Tissue Int; 2004 Oct; 75(4):338-43. PubMed ID: 15549649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin mitigates tail suspension-induced osteopenia.
    Bateman TA; Dunstan CR; Ferguson VL; Lacey DL; Ayers RA; Simske SJ
    Bone; 2000 May; 26(5):443-9. PubMed ID: 10773583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength.
    Ulrich-Vinther M; Andreassen TT
    Calcif Tissue Int; 2005 Apr; 76(4):280-6. PubMed ID: 15812581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density.
    Suzuki K; Kurose T; Takizawa M; Maruyama M; Ushikawa K; Kikuyama M; Sugimoto C; Seino Y; Nagamatsu S; Ishida H
    Diabetes Res Clin Pract; 2005 May; 68(2):117-25. PubMed ID: 15860239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Geranylgeranylacetone inhibits formation and function of human osteoclasts and prevents bone loss in tail-suspended rats and ovariectomized rats.
    Nanke Y; Kotake S; Ninomiya T; Furuya T; Ozawa H; Kamatani N
    Calcif Tissue Int; 2005 Dec; 77(6):376-85. PubMed ID: 16362462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.
    Yasuda H; Shima N; Nakagawa N; Mochizuki SI; Yano K; Fujise N; Sato Y; Goto M; Yamaguchi K; Kuriyama M; Kanno T; Murakami A; Tsuda E; Morinaga T; Higashio K
    Endocrinology; 1998 Mar; 139(3):1329-37. PubMed ID: 9492069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats.
    Mochizuki S; Fujise N; Higashio K; Tsuda E
    J Bone Miner Metab; 2002; 20(1):14-20. PubMed ID: 11810411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice.
    Zhang J; Dai J; Lin DL; Habib P; Smith P; Murtha J; Fu Z; Yao Z; Qi Y; Keller ET
    J Bone Miner Res; 2002 Jul; 17(7):1256-63. PubMed ID: 12096839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats.
    Kostenuik PJ; Capparelli C; Morony S; Adamu S; Shimamoto G; Shen V; Lacey DL; Dunstan CR
    Endocrinology; 2001 Oct; 142(10):4295-304. PubMed ID: 11564687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A toxicity profile of osteoprotegerin in the cynomolgus monkey.
    Smith BB; Cosenza ME; Mancini A; Dunstan C; Gregson R; Martin SW; Smith SY; Davis H
    Int J Toxicol; 2003; 22(5):403-12. PubMed ID: 14555415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice.
    Kostenuik PJ; Bolon B; Morony S; Daris M; Geng Z; Carter C; Sheng J
    Bone; 2004 Apr; 34(4):656-64. PubMed ID: 15050896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties.
    Ulrich-Vinther M; Schwarz EM; Pedersen FS; Søballe K; Andreassen TT
    Bone; 2005 Dec; 37(6):751-8. PubMed ID: 16169783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin.
    Byrne FR; Morony S; Warmington K; Geng Z; Brown HL; Flores SA; Fiorino M; Yin SL; Hill D; Porkess V; Duryea D; Pretorius JK; Adamu S; Manoukian R; Danilenko DM; Sarosi I; Lacey DL; Kostenuik PJ; Senaldi G
    Gut; 2005 Jan; 54(1):78-86. PubMed ID: 15591508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.
    Yano K; Tsuda E; Washida N; Kobayashi F; Goto M; Harada A; Ikeda K; Higashio K; Yamada Y
    J Bone Miner Res; 1999 Apr; 14(4):518-27. PubMed ID: 10234572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.
    Saidenberg-Kermanac'h N; Corrado A; Lemeiter D; deVernejoul MC; Boissier MC; Cohen-Solal ME
    Bone; 2004 Nov; 35(5):1200-7. PubMed ID: 15542046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.
    Hofbauer LC; Khosla S; Dunstan CR; Lacey DL; Boyle WJ; Riggs BL
    J Bone Miner Res; 2000 Jan; 15(1):2-12. PubMed ID: 10646108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Osteoclastogenesis inhibitory factor (OCIF)/OPG (a novel therapeutic candidate for the treatment of metabolic bone diseases)].
    Tsuda E
    Nihon Rinsho; 2002 Mar; 60 Suppl 3():679-87. PubMed ID: 11979969
    [No Abstract]   [Full Text] [Related]  

  • 18. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
    Schett G; Redlich K; Hayer S; Zwerina J; Bolon B; Dunstan C; Görtz B; Schulz A; Bergmeister H; Kollias G; Steiner G; Smolen JS
    Arthritis Rheum; 2003 Jul; 48(7):2042-51. PubMed ID: 12847699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats.
    Kodama Y; Nakayama K; Fuse H; Fukumoto S; Kawahara H; Takahashi H; Kurokawa T; Sekiguchi C; Nakamura T; Matsumoto T
    J Bone Miner Res; 1997 Jul; 12(7):1058-67. PubMed ID: 9200005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnesium deficiency: effect on bone and mineral metabolism in the mouse.
    Rude RK; Gruber HE; Wei LY; Frausto A; Mills BG
    Calcif Tissue Int; 2003 Jan; 72(1):32-41. PubMed ID: 12370796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.